| derazantinib (ARQ 087) / Merck (MSD) |
2016-004448-12: A study to investigate the effects of the drug ARQ 087 in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholanciocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion. Uno studio per valutare gli effetti del farmaco ARQ 087 in pazienti che hanno un tipo di tumore al dotto biliare molto esteso o che non possono essere operati, chiamato Colangiocarcinoma Intraepatico. I pazienti sono positivi alla fusione del gene FGFR2 |
|
|
| Ongoing | 3 | 100 | Europe | ARQ 087, ARQ 087, Capsule, hard | ARQULE INC, ArQule, Inc. | Inoperable or advanced FGFR2 gene fusion positive intrahepatic cholangiocarcinoma Colangiocarcinoma intraepatico inoperabile o avanzato positivo alla fusione del gene FGFR2, A type of bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion Un tipo di tumore al dotto biliare che non si può operare o molto esteso, in pazienti positivi per la fusione del gene FGFR2, Diseases [C] - Cancer [C04] | | | | |
2020-004938-38: ADVANCE: A clinical study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with gene FGFR2 fusions/rearrangements Die ADVANCE Studie: Eine einarmige, offene klinische Studie der Phase II zur Behandlung mit Atezolizumab und Derazantinib bei Patienten mit einem fortge-schrittenen intrahepatischen Cholangiokarzinom, das molekulare FGFR2 Alterationen (Gen-Fusionen/Rearrangements) aufweist |
|
|
| Not yet recruiting | 2 | 37 | Europe | Derazantinib, Derazantinib•2HCl / BAL087 / BAL0000087-001, Concentrate for solution for infusion, Capsule, hard, Tecentriq® 1.200 mg | Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, ROCHE Pharma AG, Basilea Pharmaceutica International Ltd. | Advanced non-resectable intrahepatic cholangiocarcinoma with positively confirmed FGFR2 fusion/rearrangements via NGS-Analysis, Advanced and inoperable intrahepatic bile duct cancer with positively confirmed FGFR2 genetic alterations, Diseases [C] - Cancer [C04] | | | | |
NCT05174650: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements |
|
|
| Recruiting | 2 | 37 | Europe | Atezolizumab, Tecentriq, Derazantinib, ARQ 087 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Intrahepatic Cholangiocarcinoma | 12/25 | 08/26 | | |
2019-004505-27: A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03) |
|
|
| Not yet recruiting | 1/2 | 314 | Europe | Derazantinib, Paclitaxel EVER Pharma 6 mg/ml, Cyramza 100 mg/10ml, Tecentriq 1,200 mg, Cyramza 500 mg/50ml, [Ramucirumab], [Atezolizumab], [Paclitaxel], [Derazantinib], Capsule, hard, , Concentrate for solution for infusion, Paclitaxel EVER Pharma 6 mg/ml, Cyramza 100 mg/10ml, Tecentriq 1,200 mg, Cyramza 500 mg/50ml | Basilea Pharmaceutica International Ltd., Basilea Pharmaceutica International Ltd., Allschwil, Basilea Pharmaceutica International Ltd, Allschwil, Basilea Pharmaceutica International AG, Basilea Pharmaceutica International Ltd. | HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations, Stomach cancer, Diseases [C] - Cancer [C04] | | | | |
NCT04087876: Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations |
|
|
| Available | N/A | | NA | derazantinib | Basilea Pharmaceutica | Intrahepatic Cholangiocarcinoma | | | | |
ChiCTR2000031787: A Clinical Study to Evaluate Safety and Efficacy of ARQ 087 in Chinese Inoperable, Recurrent or Metastatic Intrahepatic Cholangiocarcinoma Subjects With Advanced Solid Tumors and FGFR2 Gene Fusion Positive Who Failed at Least First-Line Systemic Therapy |
|
|
| Recruiting | N/A | 110 | | ARQ087 ;ARQ087 | Peking University Cancer Hospital & Institute; Sinovant Sciences Co., Ltd., self-financing | Solid Tumor and Intrahepatic Cholangiocarcinoma | | | | |
